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Abstract
Circulating metabolite levels are biomarkers for cardiovascular disease (CVD). Here we stud-
ied, association of rare variants and 226 serum lipoproteins, lipids and amino acids in 7,142
(discovery plus follow-up) healthy participants. We leveraged the information from multiple
metabolite measurements on the same participants to improve discovery in rare variant asso-
ciation analyses for gene-based and gene-set tests by incorporating correlated metabolites as
covariates in the validation stage. Gene-based analysis corrected for the effective number of
tests performed, confirmed established associations at APOB, APOC3, PAH, HAL and PCSK
(p<1.32x10-7) and identified novel gene-trait associations at a lower stringency threshold with
ACSL1, MYCN, FBXO36 and B4GALNT3 (p<2.5x10-6). Regulation of the pyruvate dehydro-
genase (PDH) complex was associated for the first time, in gene-set analyses also corrected
for effective number of tests, with IDL and LDL parameters, as well as circulating cholesterol
(pMETASKAT<2.41x10-6). In conclusion, using an approach that leverages metabolite measure-
ments obtained in the same participants, we identified novel loci and pathways involved in the
regulation of these important metabolic biomarkers. As large-scale biobanks continue to
amass sequencing and phenotypic information, analytical approaches such as ours will be
useful to fully exploit the copious amounts of biological data generated in these efforts.
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Author summary
Cardiovascular diseases (CVD) are the number one cause of death globally. Various meta-
bolic biomarkers including lipid and lipoprotein particles have been implicated as risk fac-
tors for the development of CVD. Understanding how these biomarkers are regulated can
lead to increased understanding of CVD aetiology and the potential identification of drug
targets. Here we take advantage of high resolution measurements on a large cohort of
7,142 healthy blood donors with whole-exome and whole-genome sequencing data to
explore the influence of rare variation on circulating metabolic biomarker levels. Using a
novel approach leveraging the information gained from various measurements on the
same participants we are able to identify a novel biological pathway involved in the regula-
tion of intermediate-density and low-density lipoproteins as well as circulating choles-
terol, confirm various established gene associations and identify potential novel gene
associations that merit further replication. This work highlights the advantages that can be
gained by combining high resolution genotypic and phenotypic measurements in one
large cohort.
Introduction
Metabolic measurements reflect an individual’s endogenous biochemical processes and envi-
ronmental exposures [1,2]. Many circulating lipids, lipoproteins and metabolites have been
previously implicated in the development of cardiovascular disease (CVD) [3–6] or used as
biomarkers for disease diagnosis or prognosis [7,8]. Understanding the genetic influence on
circulating levels of these metabolic biomarkers can help us gain insight into the biological
processes regulating these traits, lead to improved aetiological understanding of CVD and
identify novel potential therapeutic drug targets. Notable examples of candidate drug targets
with support from human genetics are LDLR [9,10], APOB [11,12] and PCSK9 [13,14].
Genome-wide association studies (GWAS) focusing on traditionally measured lipid traits
have greatly expanded our knowledge into lipid biology and to date more than 250 loci have
been robustly associated with total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and/or triglycerides (TG) [15–23]. In
addition to this, more detailed metabolic profiling using high resolution nuclear magnetic res-
onance (NMR) measurements has proven helpful to find additional lipid and small molecule
metabolism-associated loci with smaller sample sizes, and to assess pleiotropic effects of previ-
ously established loci [24–26]. An example of this, is a novel link between the LPA locus and
very-low-density lipoprotein (VLDL) metabolism (measured by high resolution NMR), with
effect sizes twice as large as those found for traditionally measured lipid traits like LDL-C and
TC, suggesting these measurements are better at capturing underlying biological processes in
lipid metabolism than traditionally measured lipid traits [25]. In this same study, by construct-
ing a genetic risk score using variants associated with lipoprotein(a) levels and using a Mende-
lian randomisation approach the authors were able to determine a causal link between
increased lipoprotein(a) levels on overall lipoprotein metabolism [25].
Despite the at scale usage of exome arrays to capture low-frequency and rare coding varia-
tion contributing to lipid and amino acid metabolism [19–22,26], large-scale sequencing stud-
ies have the added value of assessing rare variation at single nucleotide resolution across the
whole genome, or exome, including the detection of private variants which could have large
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effects on protein function. These approaches enabled, for example, the discovery of inactivat-
ing variants in key proteins which are models for drug target antagonism [27,28].
In this study, we examined the contribution of rare variation (MAF <1%) to 226 serum
metabolic measurements in 3,741 participants with whole-exome sequence (WES) data and
3,401 participants with whole-genome sequence (WGS) data from the INTERVAL cohort,
which consists of generally healthy blood donors residing in the UK.
Results
Gene-based analyses
The sample size of this study gave us limited power to detect novel single variant associations
at rare variants (power 9.7% to find an association at p<5x10-8 with MAF 0.1% and beta =
1.1), but was well-powered for common variant analysis (power 86.41% to find an association
at p<5x10-8 with MAF 1% and beta = 0.55). Therefore, single variant analyses only confirmed
established associations at 34 unique loci after meta-analysis (Ndiscovery = 3,741, Nvalidation =
3,401, S1 Table, S1 Fig). Median correlation of betas for genome-wide significant hits between
WES and WGS was 0.97.
We then sought to discover new gene-trait associations for 226 NMR metabolic biomarkers
using rare-variant (MAF <1%) aggregate tests. For this analysis we used WES data from 3,741
healthy blood donors from the INTERVAL cohort as a discovery dataset (Methods). We per-
formed two nested approaches to group rare variants; first just loss-of-function (LoF) variants
and secondly, LoF variants plus variants predicted to be likely deleterious by their Mendelian
Clinically Applicable Pathogenicity (M-CAP) score (M-CAP score >0.025) [29] (MCAP+LoF)
(Methods). To try to minimise the inclusion of predicted deleterious missense variants with
no phenotypic consequences, we restricted these variants to those with MAF<1%. As we
expect the majority of LoF variants to have an effect on protein function, we did not filter by
MAF (however ~97% of LoF variants tested had a MAF<1%). Genes were taken forward for
validation if they reached an arbitrary threshold of p<5x10-3 in the discovery dataset (S2 and
S3 Tables). Validation was performed using whole-genome sequence (WGS) data from 3,401
independent participants from the same cohort, and we present results from meta-analysis of
discovery plus validation datasets (N = 7,142) that meet Bonferroni correction for the number
of genes in the genome (0.05/20,000 genes), i.e. gene-level significance [30–32] (p<2.5x10-6,
Table 1, Methods), without further adjustment for multiple traits. After meta-analysis, five
genes (APOB, APOC3, PCSK9, PAH, HAL) were associated with 92 different traits with
p<1.32x10-7, which is the stringent significance threshold after additionally correcting for the
effective number of tested phenotypes (Table 1, Methods, S1 Fig). All five have been previ-
ously associated with their respective traits [24,33,34]. As previously suggested, we used corre-
lated metabolic biomarkers as covariates to boost power [35,36]. These correlated biomarkers
were selected for each outcome based on their phenotypic correlation in our dataset, the
genetic correlation in publicly available datasets and the metabolic biomarker supergroup
(Methods). However, to minimise the possible collider bias this could incur, we only did this
at the validation stage. This was to ensure there was at least suggestive evidence for association
in the discovery stage without using any metabolite as a covariate (Methods). This resulted in
99 traits where using other metabolic biomarkers as covariates was possible (S4 Table). As
expected, we found a significant increase in the strength of the association signal (p-value) for
traits when we used other correlated traits as covariates compared to the unadjusted tests
[35,36], with the most notable example being a>30 order of magnitude increase in association
strength for PAH and phenylalanine (S2 and S3 Tables and S5 Table, Table 1). In total, 32 of
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the known gene-trait associations met our stringent significance threshold (p<1.32x10-7) only
after adjusting for correlated traits (S2 and S3 Tables).
In addition, we found 15 gene-trait associations in seven genes meeting standard gene-level
significance before adjusting for multiple traits (p<2.5x10-6) which also had nominal evidence
of association in the validation cohort (p<0.05). These associations also have an FDR adjusted
p-value <0.3% after removing well known genes from the results list. Nine of these were gene-
trait associations in three established genes (ALDH1L1, SCARB1, LIPC, Table 1), suggesting
that other results achieving this significance threshold may warrant being prioritised for addi-
tional follow-up to establish their validity (in these genes the results are not driven by LoF vari-
ants, S6 Table).
For the four potentially novel genes associated with lipid traits, gene-trait analysis for
LDL-C and triglycerides in UK Biobank participants with WES data provided suggestive evi-
dence of association between LDL-C and B4GALNT3 (p = 0.03) (S7 Table).
Gene-set analyses
To find links between predicted LoF variants and metabolic biomarker biology, we next
explored associations of these variants in 7,150 gene-sets. To this end, we used two biological
pathway databases (Reactome, KEGG) and one database that contains expert curated disease
associated genes (DisGeNET) (S8 Table, Methods). Gene-set analysis yielded 163 gene-set-
Table 1. Genes significantly associated (p<2.5x10-6) with at least one trait in gene-based analyses focusing on loss-of-function (LoF) or predicted deleterious mis-
sense by M-CAP plus loss-of-function (MCAP+LoF). Genes that meet gene-level significance after adjusting for multiple phenotypes (p<1.32x10-7) are highlighted in
bold. Top trait: trait with the smallest p-value after meta-analysis adjusting for correlated metabolites. p-value (covs): p-value of meta-analysis (WES+WGS) after adjusting
for correlated metabolites for top trait. If NA, this analysis was not performed for this trait due to no metabolic biomarkers meeting the criteria to be included as covariates
in meta-analysis. p-value (raw): p-value of meta-analysis without adjusting for correlated metabolites for top trait. N WES: number of tested variants in WES. N WGS:
number of tested variants in WGS. AC = Allele count. N overlap: number of variants present in both WES and WGS. N traits associated: number of traits that meet gene-
wide significance after adjusting for multiple phenotypes (p<1.32x10-7), traits meeting standard gene-wide significance (2.5x10-6) in parenthesis. Driven by single variant?:
Yes if after conditioning on top associated variant the meta-analysis association disappears (p>0.05). IDL-TG: Triglycerides in IDL. XS-VLDL-TG: Triglycerides in very
small VLDL. Phe: Phenylalanine. His: Histidine. IDL-FC: Free cholesterol in IDL. IDL-P: Concentration of IDL particles. M-VLDL-L: Total lipids in medium VLDL. Gly:
Glycine. XL-HDL-FC: Free cholesterol in very large HDL. IDL-CE %: Cholesterol esters to total lipids ratio in IDL. L-VLDL-FC %: Free cholesterol to total lipids ratio in
large VLDL. XXL-VLDL-C %: Total cholesterol to total lipids ratio in extremely large VLDL.
LoF
Gene Top trait p-value
(covs)
p-value
(raw)
N WES
(AC)
p-value
(WES)
N WGS
(AC)
p-value
(WGS)
N
overlap
N traits
associated
Driven by single
variant?
APOB IDL-TG 3.20x10-13 1.72x10-10 6 (6) 2.11x10-10 5 (9) 1.97x10-3 0 45 (57) No
APOC3 XS-VLDL-TG 6.10x10-13 3.58x10-12 3 (18) 7.83x10-6 2 (23) 1.00x10-7 2 46 (56) No
MCAP+LoF
Gene Top trait p-value
(covs)
p-value
(raw)
N WES
(AC)
p-value
(WES)
N WGS
(AC)
p-value
(WGS)
N
overlap
N traits
associated
Driven by single
variant?
PAH Phe 8.33x10-63 1.67x10-28 39 (81) 1.93x10-14 41(79) 1.68x10-14 18 1 (1) No
HAL His NA 3.72x10-42 48 (177) 5.65x10-23 37 (159) 7.80x10-20 22 1 (1) No
APOC3 XS-VLDL-TG 5.46x10-11 2.15x10-10 6 (23) 1.72x10-5 6 (30) 2.91x10-7 3 26 (40) No
PCSK9 IDL-FC 2.39x10-10 1.11x10-7 15 (38) 1.70x10-4 17 (33) 3.21x10-5 3 29 (34) No
ACSL1 IDL-P 1.82x10-7 1.76x10-4 4 (5) 4.52x10-3 6 (6) 2.68x10-3 2 0 (1) Yes
MYCN M-VLDL-L 6.20x10-7 3.97x10-6 7 (8) 8.25x10-4 8 (14) 7.44x10-4 3 0 (5) No
ALDH1L1 Gly NA 4.56x10-7 33 (132) 4.34x10-5 38 (128) 2.89x10-3 19 0 (1) No
SCARB1 XL-HDL-FC% NA 4.30x10-7 24 (38) 2.90x10-4 18 (40) 7.56x10-4 10 0 (6) No
FBXO36 IDL-CE % NA 1.98x10-6 5 (62) 1.62x10-5 2 (43) 2.56x10-2 1 0 (1) Yes
B4GALNT3 L-VLDL-FC % NA 7.59x10-7 27 (721) 1.07x10-4 22 (697) 1.61x10-3 13 0 (1) No
LIPC XXL-VLDL-C
%
NA 9.04x10-7 27 (46) 1.94x10-4 29 2.53x10-3 11 0 (2) No
https://doi.org/10.1371/journal.pgen.1008605.t001
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trait associations with 14 unique gene-sets meeting Bonferroni corrected gene-set-wide signifi-
cance threshold (pmeta<2.41x10-6, Methods, S9 Table). Given that 143 gene-set-trait associa-
tions were with 13 gene-sets that included two genes with well-established roles in lipid
biology (APOB and APOC3), we repeated the test removing variants in these genes. After
removal, there was residual evidence of association (pmeta<0.05) in 102 of 143 gene-set-trait
signals representing 12 of 13 gene-sets. Of the 163 gene-set-trait associations, the remaining 20
gene-set-trait associations (in gene-sets not containing either APOB or APOC3) represent
associations of various lipoprotein-related metabolic biomarkers with the “regulation of
pyruvate dehydrogenase (PDH) complex” pathway in REACTOME (R-HSA-204174, min
p = 7.85x10-7, trait = phospholipids in intermediate density lipoproteins (IDL-PL), S9 Table).
These associations encompassed 12 LoF (allele count [AC] = 12) variants in WES and four in
WGS (AC = 6) (Fig 1). Upon further inspection, we found that the optimal rho(ρ) value in the
SKAT-O test was one, in both the WES and the WGS analyses. This is equivalent to a burden
test and suggests most variants tested in this pathway contribute to the association (i.e the sig-
nal was not driven by a single gene) [37] (S10 Table). Two variants were of particular interest
as they were present in both WES and WGS datasets, rs113309941 in Pyruvate Dehydrogenase
Complex Component X (PDHX) and rs201013643 in Pyruvate Dehydrogenase Phosphatase
Regulatory Subunit (PDPR). In PDHX, rs113309941 leads to a premature stop mutation
(Gln248Ter). It has an AC of one in both WES and WGS, and is very rare in the Genome
Aggregation Database (gnomAD) (AC = 3, allele number (AN) = 246,116). rs201013643 in
PDRP also leads to a premature stop (Arg714Ter) and is present in a single heterozygous par-
ticipant in the WES dataset and two heterozygous participants in the WGS. This variant is also
rare in gnomAD (AC = 141, AN = 275,988). The five participants carrying these two variants,
who are all unrelated (PI_HAT<0.01) to carriers of the same variant, had higher than average
values for biomarkers including cholesterol in intermediate-density lipoproteins (IDL-C) and
LDL-C (lying in upper percentile range from 44.1% to 0.03% for both traits). Additionally,
there are four unrelated heterozygous carriers of these variants in the European ancestry, UK
Biobank participants with WES data (N = 36,769), of whom three had LDL-C measured at the
baseline visit using a conventional enzymatic assay. Two of these individuals were in the upper
quartile of LDL but the third one was in the bottom 1%” (S11 Table). These results suggest
that the variants may have a deleterious but not fully penetrant impact on lipid metabolism, or
that differences between the assay platforms across the studies may lead to heterogeneous asso-
ciations. Future analyses of NMR assay measures in the UK Biobank may help to clarify this.
None of the genes in this pathway has been previously associated with these traits and there-
fore this study links these genes collectively to IDL and LDL metabolism and circulating cho-
lesterol for the first time.
Enrichment of rare variant associations in genes near established GWAS
signals in lipoprotein related metabolic biomarkers
Next, we conducted analyses to investigate whether genes near GWAS index variants associ-
ated with traditional lipid traits (HDL-C, LDL-C, TC and TG) were enriched for rare variant
associations with high resolution lipoprotein measurements, which could suggest enrichment
of effector transcripts in the gene-set. Given that this was a hypothesis-driven approach using
established signals, to boost discovery power we pooled together both WES and WGS data
into a single dataset of 7,142 participants. First, we extracted from the GWAS catalog (release
27-09-2017) the “reported genes” near signals that have been associated with HDL-C, LDL-C,
TC or TG and created four gene-sets (S12 Table). We only focused on genes that were
reported unambiguously (i.e. where only one gene is reported) since for associations where
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more than one gene is reported, it is possible that only one will be the effector gene and rare
variants from the non-effector genes will only add noise to the analysis and therefore reduce
power. We grouped rare variants in the gene-set using two nested approaches (LoF and
MCAP+LoF) and ran SKAT-O on the gene-sets for 157 lipoprotein and lipid traits. Using this
approach we found associations (p<0.005 correcting for effective number of tests, Methods)
for genes near HDL-C GWAS signals with 18 HDL-related traits (S13 Table), the strongest
association being with esterified cholesterol in extra-large HDL (XL-HDL-CE, p = 2.83x10-5,
MCAP+LoF). Associations (p<0.005, Methods) in two XL-HDL-C related traits remained
after removing variants in genes known to be involved in conditions leading to abnormal lipid
levels or genes where functional work has shown an effect on HDL-C (S14 Table, Methods),
and after conditioning on associated common variants near reported genes (XL-HDL-CE,
p = 0.002 and XL-HDL-C, p = 0.004). These findings suggest that there is a contribution to the
phenotypic variance of these traits by rare coding variants in genes near GWAS signals without
a known role in HDL metabolism, which may represent novel effector transcripts.
Fig 1. Loss-of-function (LoF) variants in regulation of pyruvate dehydrogenase (PDH) complex pathway. a) Figure adapted from REACTOME pathway browser
[77]. Highlighted in red are protein complexes that carry LoF variants in INTERVAL WES or WGS. b) List of genes, consequences and allele count (AC) of LoF
variants in the different protein complexes in the pathway.
https://doi.org/10.1371/journal.pgen.1008605.g001
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Enrichment of rare variation in tails of the phenotypic distribution of
lipoprotein and glyceride related traits
Finally, we aimed to investigate whether participants at the extreme tails of the phenotype dis-
tribution for 106 lipoprotein and lipid traits harboured rare coding variants likely to be con-
tributing to their phenotype. We used the WES dataset as a discovery dataset and the WGS
dataset for validation. An arbitrary cut-off of 10 participants at each tail was used to define the
tails for all of the 106 traits (Methods). After meta-analysis, we found an enrichment of delete-
rious rare variation (validation ppermutation<0.05, meta-analysis ppermutation<0.00037, Methods,
Table 2, S15 Table) in hyperlipidaemia related genes in the lower tail of cholesterol in small
VLDL (S-VLDL-C), esterified cholesterol in small VLDL (S-VLDL-CE) and concentration of
extra small VLDL particles (XS-VLDL-P), and rare variation in HDL remodelling related
genes in the lower tail of concentration of small HDL particles (S-HDL-P). We still observed
nominal evidence of association in the WES and WGS datasets for the S-VLDL-C and
XS-VLDL-P results using a 0.5% percentile cut-off for the tails but no evidence of association
was found when using a 1% percentile cut-off (S16 Table). This is likely due to the fact that by
increasing the number of participants taken from the tails, we are decreasing the average dis-
tance to the mean of the trait distribution and diluting signal coming from true extreme
values.
Discussion
Exploring rare coding variation provides an opportunity to gain insights into biological pro-
cesses regulating the circulating levels of metabolic biomarkers. Here we take advantage of the
combination of sequencing data and high-resolution NMR measurements to elucidate how
this variation influences multiple metabolic measurements in a healthy cohort of UK blood
donors.
To identify genes and gene-sets associated with metabolic biomarkers, we used a two-stage
gene-based analysis using WES data for discovery (Ndiscovery = 3,741) and WGS data for valida-
tion (Nvalidation = 3,401). Rare-variant aggregation tests were used to identify genes harbouring
multiple rare coding variants associated with metabolic biomarkers. To gain power at the vali-
dation stage we adjusted analyses for correlated traits, an approach previously described for
single variant analysis [36]. This yielded significant power gains, notably for the known associ-
ation of PAH with phenylalanine levels, where adjusting for 71 phenotypically correlated traits
resulted in a greater than 30-fold magnitude change in the statistical evidence of association
after meta-analysis. Overall, this approach yielded 4,114 gene-trait associations taken forward
for validation (pdiscovery<5x10
-3). After meta-analysis, besides recapitulating previous associa-
tions in eight known genes (APOB, APOC3, PAH, HAL, PCSK9, ALDH1L1, SCARB1 and
LIPC, Table 1), this method also identified four genes (ACSL1, MYCN, B4GALNT3, FBXO36)
that met standard gene-level significance (p<2.5x10-6, Table 1) in at least one gene-trait asso-
ciation test. Of these, ACSL1 and MYCN have been previously linked to lipid metabolism [39–
41], and therefore will merit additional follow-up. Of these four genes only B4GALNT3 had
evidence of association with a traditional lipid trait (LDL-C, p<0.05) in UK Biobank although
it is important to note that the lead associations in the INTERVAL study for these genes were
with specific lipoprotein parameters and none of these genes except ASCL1 (serum triglycer-
ides, p = 0.03) showed evidence of association with a traditional lipid trait in the INTERVAL
NMR data.
ACSL1, which codes for long-chain-fatty-acid—CoA ligase 1, is the predominant isoform
of ACSL in the liver. The gene was associated with concentration of IDL particles in this study
(p = 1.82x10-7), and its deficiency in the liver has been shown to reduce synthesis of
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triglycerides and beta oxidation, and alter the fatty acid composition of major phospholipids
[42]. An intronic variant (rs60780116) in ACSL1 has been associated with risk of Type 2 diabe-
tes [43] and elevated expression of ACSL1 has been shown to be an independent risk factor for
acute myocardial infarction after taking into account conventional risk factors [44].
MYCN encodes N-myc proto-oncogene protein and its amplification can lead to tumori-
genesis [45,46]. Previous animal studies have shown that inhibition of MYCN can lead to accu-
mulation of intracellular lipid droplets in tumour cells [41]. Here we find association between
MYCN and concentration of lipids, phospholipids and triglycerides in medium VLDL, total
particle concentration of medium VLDL and triglycerides in small VLDL (min p = 6.20x10-7,
Table 1, S3 Table).
The other two genes do not have any obvious link to lipid metabolism. B4GALNT3 encodes
beta-1,4-N-acetyl-galactosaminyl transferase 3. This protein mediates the N,N’-diacetyllactose-
diamine formation on gastric mucosa [47]. Mouse knockouts have been associated with
abnormal tail movements, abnormal retinal pigmentation and increased circulating alkaline
phosphatase levels [48] and variants near the gene have been associated with height and hip
circumference adjusted for BMI in human GWAS [49,50]. FBXO36 is a member of the F-
box protein family, a family known to be involved in protein ubiquitination [51]. Replication
of these signals in additional studies would represent a novel link between these genes and
lipid metabolism.
In gene-set analysis, the “regulation of pyruvate dehydrogenase (PDH) complex” pathway
was newly associated with 20 traits, mostly related to IDL and LDL lipoproteins. None of the
genes in this pathway have been previously linked to any of these phenotypes, and our data
suggest the signal arises from a cumulative effect of LoF variants in different genes in the path-
way (Fig 1), which represents a novel link between this pathway and lipoprotein metabolism.
Notably, one of the carriers of the PDHX Gln248Ter variant was in the top 0.03% for LDL-C
in the whole INTERVAL cohort (4.1 mmol/l, 158.0 mg/dl) and had no predicted deleterious
missense mutations in known hypercholesterolemia genes (PCSK9, APOB or LDLR) suggest-
ing this novel protein-truncating variant may be a genetic cause for their high LDL-C levels.
The other carrier of this variant was in the top 19.3% percentile of the whole cohort
(N = 46,083), but within the normal clinical range (1.8 mmol/l). Since we lack information on
participants’ use of lipid-lowering medication, the degree to which this variant influences the
observed LDL-C levels is difficult to assess. The PDH complex has been shown to be crucial
Table 2. Gene-sets where there is a nominally significant enrichment of rare variation in the tails of a lipid or lipoprotein measurement (p>0.05) in both WES and
WGS. – Highlighted in bold are gene-sets that are significant after meta-analysis using Stouffer’s method [38] and after adjusting for multiple traits (p< = 0.00037). WES
P: permutation p in WES. WGS P: permutation p in WGS. Meta-P: p after meta-analysis using Stouffer’s method. S-VLDL-FC: Free cholesterol in small VLDL.
XS-VLDL-C: Cholesterol in very small VLDL. S-VLDL-C: Cholesterol in small VLDL. XS-VLDL-P: Concentration of very small VLDL particles. S-VLDL-CE: Cholesterol
esters in small VLDL. S-HDL-P: Concentration of small HDL particles.
Upper tails
Trait WES P WGS P Meta-P Gene-set
S-VLDL-FC 3.3x10-2 2.37x10-2 3.45x10-3 Hypertriglyceridemia_HPO
XS-VLDL-C 3.3x10-2 2.37x10-2 3.45x10-3 Hypertriglyceridemia_HPO
Lower tails
Trait WES P WGS P Meta-P Gene-set
S-VLDL-C 5.8x10-3 2.31x10-3 7.61x10-5 Hyperlipidaemia
XS-VLDL-P 1.85x10-2 7x10-4 9.42x10-5 Hyperlipidaemia
S-VLDL-CE 5.8x10-3 6.75x10-3 2.07x10-4 Hyperlipidaemia
S-HDL-P 2.72x10-3 1.84x10-2 2.89x10-4 HDL_remodeling
S-HDL-P 4.10x10-2 3.92x10-2 8.x24x10-3 Hypertriglyceridemia_CTD
https://doi.org/10.1371/journal.pgen.1008605.t002
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for metabolic flexibility, i.e. the capacity to adjust fuel oxidation based on nutrient availability,
which itself has been shown to play a role in cardiovascular disease [52].
In analyses aiming at identifying effector transcripts at established GWAS loci associated
with traditional lipid measurements (HDL-C, LDL-C, TC and TG), we established that
reported genes mapping near HDL-C associated loci were enriched for rare coding variants
associated with multiple HDL-related measurements. The results remained significant
(p<0.005) after removing genes known to be directly involved in HDL metabolism. This sug-
gests that even though no single gene in the gene-set has sufficient statistical evidence of asso-
ciation, rare variants in this gene-set contribute to variation in these traits, and that this gene-
set is enriched for additional effector transcripts.
Finally, we showed that one can detect enrichment of rare variation in genes involved in
lipoprotein metabolism in phenotypic extremes of some of these NMR measurements. Specifi-
cally, we showed enrichment of rare variants in hyperlipidaemia related genes in participants
with very low levels of cholesterol and esterified cholesterol in small VLDL, and very low levels
of the total concentration of small VLDL particles. Enrichment of rare variants in HDL remod-
elling genes in participants with very low levels of small HDL particles was also observed.
Given that high levels of small HDL particles have been previously associated with higher inci-
dence of ischemic stroke [53] some of these variants could have protective effects. These results
are in agreement with previous work on LDL-C [23] and HDL-C [54] that show that common
polygenic signals seem to have a higher impact on the higher extremes of lipid traits whereas
there is evidence for a higher prevalence of rare variation on the lower extremes [54]. This is
also expected since the INTERVAL cohort consists of predominantly healthy blood donors
and therefore might be depleted of individuals with rare “damaging” variants. Our study bene-
fits from utilising a novel approach incorporating correlated metabolite information in rare
variant association analyses to boost power under a discovery plus validation study design.
This kind of approach will prove useful as we continue to amass deeply phenotyped and
sequenced biobanks. Whereas other similar studies [20,26,55] have been more lenient and not
accounted for the multiple phenotypes tested, here in gene-based analyses we attempted to
overcome this limitation by accounting for the effective number of tests performed, acknowl-
edging this burden of proof limited the power of our study.
One limitation of studies using sequencing data is that some of the singleton variants that
contribute to the rare variant tests might be false positives as they have not been validated with
a different molecular approach. We tried to overcome this limitation by using a two-stage
design in our gene-based and gene-set analyses requiring evidence of association in the two
independent datasets. This approach should decrease the possibility of false-positive findings
as the likelihood that the same gene or gene-set would be a false-positive in both WES and
WGS datasets is decreased. Additionally, for the novel association of the PDH pathway with
multiple lipid traits, we manually inspected the depth of coverage for all variants tested and
found that all of them were well supported with a min DP of 19 for the alternative allele in the
WES dataset except for one participant with DP<9 for a doubleton in the WGS dataset (S17
Table).
Altogether, our results show that focusing on rare variation and deep metabolic phenotyp-
ing provides new insights into circulating metabolic biomarker biology. This argues for the
expansion of deeper molecular phenotyping as part of large cohort sequencing efforts to gain
further understanding of the role of rare coding variation on circulating metabolic biomarkers
which may potentially lead to novel drug target discovery and/or provide additional genetic
validation for specific targets.
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Methods
Participants
The INTERVAL cohort consists of nearly 50,000 predominantly healthy blood donors in the
UK [56]. All participants were genotyped using the Affymetrix UK Biobank Axiom Array and
imputed using a combined UK10K-1000G Phase III imputation panel [57]. A subset of 4,502
participants was selected for whole-exome sequencing (WES) [58] and another subset of 3,762
was selected for whole-genome sequencing (WGS). There was an overlap of 54 participants in
both datasets.
Sequencing and genotype calling
WES and WGS were performed at the Wellcome Sanger Institute (WSI) sequencing facility.
For WES, sheared DNA was prepared for Illumina paired-end sequencing and enriched for
target regions using Agilent’s SureSelect Human All Exon V5 capture technology (Agilent
Technologies; Santa Clara, California, USA). The exome capture library preparation was
sequenced using the Illumina HiSeq 2000 platform as paired-end 75 bp reads. Reads were
aligned to the GRCh37 human reference genome using BWA (v0.5.10) [59]. GATK Haploty-
peCaller v3.4 [60] was used for variant calling and recalibration. For WGS, sheared DNA was
prepared for Illumina paired-end sequencing. Sequencing was performed using the Illumina
HiSeq X platform as paired-end 75 bp reads. Reads were aligned to the GRCh38 human refer-
ence genome using mostly BWA (v.0.7.12) although a subset of samples was aligned with
v.0.7.13 or v.0.7.15. GATK HaplotypeCaller v3.5 was used for variant calling and recalibration.
We extracted coordinates from the VCF files that mapped to regions targeted in the WES. We
then used custom scripts to transform coordinates of variants to GRCh37 human reference.
Sample QC
For WES data we filtered out samples based on the following criteria: i) withdrawn consent; ii)
estimated contamination >3% according to the software VerifyBamID [61]; iii) sex inferred
from genetic data different from sex supplied; iv) non-European samples after manual inspec-
tion of clustering in 1000G principal component analysis (PCA) and choosing cutoffs on the
first 2 PCs; v) heterozygosity outliers (samples +/- 3 SD away from the mean number of het-
erozygous counts); vi) non-reference homozygosity outliers (samples +/- 3 SD away from the
mean number of non-reference homozygous counts); vii) outlier Ti/TV rates (transition to
transversion ratio +/- 3 SD away from the mean ratio); viii) excess singletons (number of sin-
gleton variants>3 SD from the cohort mean). After quality control 4,070 WES samples were
kept. For WGS data we filtered out samples based on the following criteria: i) estimated con-
tamination >2% according to software VerifyBamID; ii) non-reference discordance (NRD)
with genotype data on the same samples >4%; iii) population outliers from PCA (PC1>0 and
minimum PC2); iv) heterozygosity outliers (samples +/- 3 SD away from the mean number of
heterozygous counts); v) number of third-degree relatives (proportion IBD (PI_HAT) >0.125)
>18, vi) overlap with WES. After quality control 3,670 WGS samples were kept. The QC in
WGS was done to maximise sample retention while losing low quality ones building upon pre-
vious work with similar data [62].
In UK Biobank, we filtered out samples based on the following criteria: i) withdrawn con-
sent; ii) sex-mismatch between the sex inferred from the genetic data and the reported sex; iii)
non-European ancestry according to genetic principal components of ancestry; iv) relatedness
(third degree relatives in the UK Biobank data set). After quality control 36,769 WES samples
were kept.
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Variant QC
For variants with MAF>1% we used the following thresholds to exclude variants: i) VQSR:
99.90% tranche for WES and 99% tranche for WGS; ii) missingness >3%; iii) HWE p<1x10-5.
For variants with MAF�1% the following thresholds were used: i) VQSR: 99.90% tranche for
WES, 99% tranche for WGS SNPs and 90% tranche for WGS indels; ii) GQ:<20 for SNPs and
<60 for indels; iii) DP<2; iv) AB>15 &<80 for heterozygous variants. After genotype-level
QC (GQ,DP,AB) only variants with <3% missingness were kept. 1,716,946 variants were kept
in the final WES release and 1,724,250 in the final WGS release.
For the UK Biobank WES data, we used the FE (GATK) callset and checked the depth of
coverage for the regions targeting the novel genes. We removed monomorphic variants, vari-
ants with call rate < 95% and those with Hardy-Weinberg Equilibrium p-value< 1x10-15.
Phenotype QC
A total of 230 metabolic biomarkers were produced by the serum NMR metabolomics plat-
form (Nightingale Health Ltd.) [63] on 46,097 samples in the INTERVAL cohort. Glucose, lac-
tose, pyruvate and acetate were excluded initially due to unreliable measurements. Conjugated
linoleic acid and conjugated linoleic acid to total fatty acid ratio were set to missing for 3585
samples showing signs of peroxidation. Creatinine levels were set to missing for 1993 samples
with isopropyl alcohol signals. Glutamine levels were set to missing for 347 samples that
showed signs of glutamine to glutamate degradation. Samples with more than 30% missing-
ness or identified as EDTA plasma were removed. After this step, for each pair of related sam-
ples (PI_HAT>0.125) we kept only one, preferentially keeping samples with the lowest
missingness in WES or lowest NRD in WGS. Phenotypes were rank-based inverse normalised
for all participants. We then separately performed linear regression for WES and WGS adjust-
ing for age, gender, centre, processing duration, month of donation and 10 PCs. Residuals
from both linear regressions were used as the outcome variables in all subsequent analyses.
After this final step we kept 3,741 samples in the WES dataset and 3,401 samples in the WGS
dataset.
LDL-C, HDL-C, total cholesterol and triglycerides were measured using enzymatic assays
on a Beckman Coulter AU5800. Phenotypes in UK Biobank were rank-based inverse normal-
ised within aliquot and combined, removing participants on lipid-lowering therapy (UKBB
data codes 6177_or_6153 coded as “Cholesterol lowering medication”).
Gene-based analyses
Coding variant consequences were annotated with VEP [64] using Ensembl gene-set version
75 for the hg19/GRCh37 human genome assembly. Loss-of–function (LoF) variants were
annotated with a VEP plugin: LOFTEE (https://github.com/konradjk/loftee). M-CAP scores
were downloaded and we extracted all missense variants with AC> = 1 in the WES or WGS
datasets [29]. Two different nested tests were used to group rare variants into testable gene
units: predicted to be high confidence LoF by LOFTEE in any transcript of the gene, and the
same LoF variants plus rare (MAF <1%) missense variants mapping to any transcript of the
gene predicted to be likely deleterious by M-CAP (M-CAP score >0.025) (MCAP+LoF).
We performed rare-variant aggregation tests as implemented in the SKAT-O R package
[37,65]. For the LoF tests, we performed a burden test (rho = 1) whereas for the MCAP+LoF
tests we used the optimal unified approach (method =“optimal.adj”). Genes were taken for-
ward for validation if p<5x10-3.
Corresponding MCAP+LoF rare-variant aggregation tests for the four novel genes (ACSL1,
MYCN, FBXO36 and B4GALNT3) were performed in the European ancestry, unrelated
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participants in UK Biobank, adjusting for age, sex, aliquot and 10 principal components. Mis-
sense variants in any transcript were annotated with M-CAP scores on build 38 using ANNO-
VAR[66].
Adjusting for correlated phenotypes can increase power in single point association analyses
[36], therefore to increase power, we implemented a strategy to incorporate information from
the multiple phenotypes measured in our dataset. To minimise chances of a false positive asso-
ciation we only adjusted for phenotypes as covariates at the validation stage ensuring evidence
of association in discovery stage was present without adjustment for covariates. In order for a
metabolic biomarker to be selected as a covariate in the validation stage, the following condi-
tions had to be met: i) no evidence of genetic correlation (p>0.05) with outcome using publicly
available summary statistics from Kettunen et al (2016) [25]; ii) phenotypic correlation in our
dataset>10%; iii) not belonging to same metabolic biomarker supergroup as outcome (S18
Table). This approach resulted in 99 eligible NMR traits for which other traits could be used as
covariates. METASKAT [67] was used to perform meta-analysis using the same parameters as
in discovery. A signal was considered to replicate if: i) it met our Bonferroni corrected gene-
level significance threshold (p<1.32x10-7); ii) >2 variants were tested; iii) it was nominally sig-
nificant (p<0.05) in the unadjusted test for WGS (i.e. without adjusting for correlated traits).
The Bonferroni corrected gene-level significance threshold was chosen after adjusting the stan-
dard gene-level significance threshold (2.5x10-6) for 19 PCs explaining >95% of the variance
of 226 metabolic biomarkers, an approach previously used in similar studies using the same
NMR platform [24,25].
To test if a single variant was driving an observed association, we performed leave-one-out
analysis for all variants contributing to the test. An association was considered to be driven by
a single variant if, after removing it the test resulted in a non-significant association (p>0.05).
Gene-set analyses
To perform gene-set analysis we obtained a curated gene-disease list from DisGeNET [68,69]
and gene lists of metabolic pathways from KEGG [70–72] and Reactome [73,74] (S8 Table).
The gene-disease list obtained from DisGeNET, combines expert curated gene-disease associa-
tions from the following databases: a) CTD (Comparative Toxicogenomics Database); b) UNI-
PROT; c) ORPHANET (an online rare disease and orphan drug data base); d) PSYGENET
(Psychiatric disorders Gene association NETwork); and e) HPO (Human Phenotype Ontology).
We limited analysis to gene-sets with more than three genes. Finally we extracted loss-of-func-
tion variants from genes in the gene-sets and ran SKAT-O (method =“optimal.adj”) for each of
the traits. Similarly to the gene-based analysis, we used WES data as discovery, and took signals
forward for validation in WGS if p<0.01. Covariate selection for correlated traits was performed
as described in the gene-based analysis. The Gene-set-wide significance threshold was calcu-
lated by first estimating the effective number of gene-sets tested given the high overlap amongst
them. Using PCA we estimated that 1094 PCs explain>95% of the variance in gene-sets. The
significance threshold was therefore calculated as: 0.05/(1094�19) = 2.41x10-6 where 19 corre-
sponds to the effective number of phenotypes tested as described above. A signal was considered
to replicate if after meta-analysis: i) it met Bonferroni corrected gene-set-wide significance
threshold (pmeta<2.41x10-6); ii)>2 variants were tested; iii) it was nominally significant
(pvalidation<0.05) in the unadjusted test for WGS (i.e without adjusting for correlated traits).
Genes near GWAS signals
GWAS catalog data files (release 27-09-2017) were downloaded from https://www.ebi.ac.uk/
gwas/docs/file-downloads [75]. We focused on GWAS loci associated with HDL-C, LDL-C,
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TC and TG. We extracted all reported genes for GWAS loci that were associated at genome-
wide significance (p<5x10-8) excluding cases where the “REPORTED GENE” value was: i) NR
(not reported); ii) intergenic; iii) APO(APOE) cluster; iv) HLA-area (S12 Table). These vari-
ants were also further used as covariates in sensitivity analyses. For this analysis, we ran
SKAT-O using the optimal unified approach (method =“optimal.adj”) on the four gene-sets
(HDLC reported, LDLC reported, TC reported, TG reported, S12 Table). The list of genes
known to be involved in conditions leading to abnormal lipid levels was created extracting rel-
evant genes from the DisGeNET and Reactome gene lists. Afterwards, we conducted a manual
review of the published literature to remove genes where functional work in mouse or human
has revealed a direct role of the gene in HDL metabolism (S12 Table). The search terms used
were “[gene name] loss of function HDL” and “[gene name] knockout HDL”. Significance
threshold (p<0.005) was determined by correcting for 10 PCs explaining >95% of the variance
of the traits used in this analysis.
Tails analysis
For this analysis, we used all lipoprotein and lipid traits but excluded derived measures (lipid
ratios) resulting in 106 traits (S18 Table). We focused on likely deleterious missense and loss-
of-function variation in lipid metabolism and disease gene-sets (S19 Table) with an allele
count<10 in each dataset. We chose an arbitrary cut-off of 10 participants with the highest
and lowest values for the traits to define our tails for all 106 traits. Given the high phenotypic
correlation of our traits, there was a high overlap of participants at the tails of the distributions
(S2 and S3 Figs) so we removed traits that shared> = 8 participants with any other trait
reducing the number of tested traits to 50. For each trait, total deleterious allele count from
each gene-set for upper and lower tails was obtained and an empirical p was calculated by
performing 10,000 permutations extracting 10 random participants from the phenotype distri-
bution and counting the number of deleterious alleles from the gene-set. This was done sepa-
rately for WES (discovery) and WGS (validation) and only those that were nominally
significant (ppermutation<0.05) in WES were meta-analysed. The significance threshold for the
combined WES+WGS meta-analysis (ppermutation = 0.00037) was chosen by correcting for 9
PCs explaining >95% of the traits variance and 15 pathways. Enrichment was declared if the
test reached this significance threshold after meta-analysis and if in addition. we observed
ppermutation<0.05 in the validation dataset. Meta-analysis was done using Stouffer’s method
[38] as implemented in the metap package [76] in R.
Ethics statement
After reading study leaflets and participating in a discussion with donor carer staff, eligible
donors were asked to complete the trial consent form before giving a blood donation. The
National Research Ethics Service approved (11/EE/0538) this study.
Supporting information
S1 Fig. P-value thresholds used in each analysis. Neff refers to effective N. Yellow boxes high-
light analyses adjusted for correlated metabolites.
(TIF)
S2 Fig. Overlap of top 10 participants in the tails of 106 lipid and lipoprotein traits. Col-
umns represent the top 10 participants of at least one trait. Rows represent the 106 lipid
and lipoprotein traits used in this analysis. A blue square represents presence of a participant
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in the top 10 participants for its respective trait.
(TIF)
S3 Fig. Overlap of bottom 10 participants in the tails of 106 lipid and lipoprotein traits.
Columns represent the lower 10 participants of at least one trait. Rows represent the 106
lipid and lipoprotein traits used in this analysis. A blue square represents presence of a partici-
pant in the lower 10 participants for its respective trait.
(TIF)
S1 Table. Single point association analyses results.
(XLSX)
S2 Table. Gene-trait associations with p< 5x10-3 in discovery stage (LoF, N = 3,741), and
their corresponding association results in validation (N = 3,401) and combined meta-anal-
ysis (N = 7,142).
(XLSX)
S3 Table. Gene-trait associations with p< 5x10-3 in discovery stage (MCAP+LoF,
N = 3,741) and corresponding validation results (N = 3,401) and combined meta-analysis
results (N = 7,142).
(XLSX)
S4 Table. Phenotypes where adjustment for correlated biomarkers as covariates was per-
formed.
(XLSX)
S5 Table. Variants tested in significant gene-based results.
(XLSX)
S6 Table. Gene-trait associations for candidate novel loci using only LoF.
(XLSX)
S7 Table. LoF + MCAP SKAT-O gene-based results for LDL and triglycerides in the white,
unrelated samples with whole-exome sequence data in UK Biobank.
(XLSX)
S8 Table. Gene sets used in gene set analyses.
(XLSX)
S9 Table. Gene set analyses results.
(XLSX)
S10 Table. Rho values in SKAT-O tests for "R-HSA-204174" associated traits.
(XLSX)
S11 Table. LDL measurements for white, unrelated participants in UK Biobank
(N = 36,769) with whole-exome sequence data carring LoF variants rs113309941 or
rs201013643.
(XLSX)
S12 Table. Gene sets used for enrichment of genes near GWAS signals analyses.
(XLSX)
S13 Table. Results for SKAT-O analysis on gene sets built from lists of genes near estab-
lished GWAS loci using two nested approaches (LoF and MCAP+LoF).
(XLSX)
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S14 Table. Sensitivity analysis for significant results (p<0.005) in SKAT-O analysis on
gene sets built from lists of genes near established GWAS loci.
(XLSX)
S15 Table. Detailed results for gene sets with enriched rare variation in tails of lipoprotein
traits.
(XLSX)
S16 Table. Sensitivity analyses for rare variant enrichment in tails analysis using different
percentile cutoffs to define tails of the phenotypic distribution.
(XLSX)
S17 Table. Gene set variants DP.
(XLSX)
S18 Table. List of traits and analyses where they were used.
(XLSX)
S19 Table. List of gene sets used for tails analyses.
(XLSX)
Acknowledgments
Participants in the INTERVAL randomised controlled trial were recruited with the active col-
laboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported
field work and other elements of the trial. A complete list of the investigators and contributors
to the INTERVAL trial is provided in reference [56]��. The academic coordinating centre
would like to thank blood donor centre staff and blood donors for participating in the INTER-
VAL trial.
This research has been conducted using the UK Biobank Resource under Application
Number 44448.
��INTERVAL Trial Group. Efficiency and safety of varying the frequency of whole blood
donation (INTERVAL): a randomised trial of 45 000 donors. Lancet. 2017 Nov 25;390
(10110):2360–2371.
We thank the Human Genetics Informatics (HGI) team at the Wellcome Sanger Institute
for their contribution. We would also like to thank Patrick Short for discussions.
Author Contributions
Conceptualization: Inês Barroso.
Data curation: Klaudia Walter, Kousik Kundu.
Formal analysis: Fernando Riveros-Mckay, Clare Oliver-Williams, Savita Karthikeyan.
Funding acquisition: Willem H. Ouwehand, David Roberts, Emanuele Di Angelantonio, John
Danesh, Adam S. Butterworth, Inês Barroso.
Investigation: Fernando Riveros-Mckay, Clare Oliver-Williams, Savita Karthikeyan, Klaudia
Walter, Kousik Kundu.
Methodology: Fernando Riveros-Mckay, Clare Oliver-Williams.
Resources: Klaudia Walter, Kousik Kundu, Willem H. Ouwehand, David Roberts, Emanuele
Di Angelantonio, Nicole Soranzo, John Danesh, Adam S. Butterworth, Inês Barroso.
PLOS GENETICS The influence of rare variants in circulating metabolic biomarkers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008605 March 9, 2020 15 / 19
Supervision: Nicole Soranzo, Eleanor Wheeler, Eleftheria Zeggini, Adam S. Butterworth, Inês
Barroso.
Validation: Fernando Riveros-Mckay.
Visualization: Fernando Riveros-Mckay.
Writing – original draft: Inês Barroso.
Writing – review & editing: Eleftheria Zeggini, Adam S. Butterworth, Inês Barroso.
References
1. Athersuch TJ, Keun HC (2015) Metabolic profiling in human exposome studies. Mutagenesis 30: 755–
762. https://doi.org/10.1093/mutage/gev060 PMID: 26290610
2. Lydic TA, Goo YH (2018) Lipidomics unveils the complexity of the lipidome in metabolic diseases. Clin
Transl Med 7: 4. https://doi.org/10.1186/s40169-018-0182-9 PMID: 29374337
3. Arsenault BJ, Boekholdt SM, Kastelein JJ (2011) Lipid parameters for measuring risk of cardiovascular
disease. Nat Rev Cardiol 8: 197–206. https://doi.org/10.1038/nrcardio.2010.223 PMID: 21283149
4. Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384: 626–635.
https://doi.org/10.1016/S0140-6736(14)61177-6 PMID: 25131982
5. Varbo A, Benn M, Nordestgaard BG (2014) Remnant cholesterol as a cause of ischemic heart disease:
evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment.
Pharmacol Ther 141: 358–367. https://doi.org/10.1016/j.pharmthera.2013.11.008 PMID: 24287311
6. Wyler von Ballmoos MC, Haring B, Sacks FM (2015) The risk of cardiovascular events with increased
apolipoprotein CIII: A systematic review and meta-analysis. J Clin Lipidol 9: 498–510. https://doi.org/
10.1016/j.jacl.2015.05.002 PMID: 26228667
7. Geng P, Ding Y, Qiu L, Lu Y (2015) Serum mannose-binding lectin is a strong biomarker of diabetic reti-
nopathy in chinese patients with diabetes. Diabetes Care 38: 868–875. https://doi.org/10.2337/dc14-
1873 PMID: 25758771
8. Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, et al. (2015) Oxidized low-density lipopro-
tein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci 52: 70–85. https://doi.org/10.
3109/10408363.2014.992063 PMID: 25537066
9. Hobbs HH, Brown MS, Goldstein JL (1992) Molecular genetics of the LDL receptor gene in familial
hypercholesterolemia. Hum Mutat 1: 445–466. https://doi.org/10.1002/humu.1380010602 PMID:
1301956
10. Shichiri M, Tanaka A, Hirata Y (2003) Intravenous gene therapy for familial hypercholesterolemia using
ligand-facilitated transfer of a liposome:LDL receptor gene complex. Gene Ther 10: 827–831. https://
doi.org/10.1038/sj.gt.3301953 PMID: 12704424
11. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, et al. (1989) Association between a specific
apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A 86:
587–591. https://doi.org/10.1073/pnas.86.2.587 PMID: 2563166
12. Gebhard C, Huard G, Kritikou EA, Tardif JC (2013) Apolipoprotein B antisense inhibition—update on
mipomersen. Curr Pharm Des 19: 3132–3142. https://doi.org/10.2174/13816128113199990312 PMID:
23317401
13. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, et al. (2003) Mutations in PCSK9 cause auto-
somal dominant hypercholesterolemia. Nat Genet 34: 154–156. https://doi.org/10.1038/ng1161 PMID:
12730697
14. Duff CJ, Hooper NM (2011) PCSK9: an emerging target for treatment of hypercholesterolemia. Expert
Opin Ther Targets 15: 157–168. https://doi.org/10.1517/14728222.2011.547480 PMID: 21204732
15. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical
and population relevance of 95 loci for blood lipids. Nature 466: 707–713. https://doi.org/10.1038/
nature09270 PMID: 20686565
16. Asselbergs FW, Guo Y, van Iperen EP, Sivapalaratnam S, Tragante V, et al. (2012) Large-scale gene-
centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 91: 823–838.
https://doi.org/10.1016/j.ajhg.2012.08.032 PMID: 23063622
17. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al. (2013) Discovery and refinement
of loci associated with lipid levels. Nat Genet 45: 1274–1283. https://doi.org/10.1038/ng.2797 PMID:
24097068
PLOS GENETICS The influence of rare variants in circulating metabolic biomarkers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008605 March 9, 2020 16 / 19
18. Albrechtsen A, Grarup N, Li Y, Sparso T, Tian G, et al. (2013) Exome sequencing-driven discovery of
coding polymorphisms associated with common metabolic phenotypes. Diabetologia 56: 298–310.
https://doi.org/10.1007/s00125-012-2756-1 PMID: 23160641
19. Peloso GM, Auer PL, Bis JC, Voorman A, Morrison AC, et al. (2014) Association of low-frequency and
rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.
Am J Hum Genet 94: 223–232. https://doi.org/10.1016/j.ajhg.2014.01.009 PMID: 24507774
20. Surakka I, Horikoshi M, Magi R, Sarin AP, Mahajan A, et al. (2015) The impact of low-frequency and
rare variants on lipid levels. Nat Genet 47: 589–597. https://doi.org/10.1038/ng.3300 PMID: 25961943
21. Tang CS, Zhang H, Cheung CY, Xu M, Ho JC, et al. (2015) Exome-wide association analysis reveals
novel coding sequence variants associated with lipid traits in Chinese. Nat Commun 6: 10206. https://
doi.org/10.1038/ncomms10206 PMID: 26690388
22. Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, et al. (2017) Exome-wide association study of
plasma lipids in >300,000 individuals. Nat Genet 49: 1758–1766. https://doi.org/10.1038/ng.3977
PMID: 29083408
23. Natarajan P, Peloso GM, Zekavat SM, Montasser M, Ganna A, et al. (2018) Deep-coverage whole
genome sequences and blood lipids among 16,324 individuals. Nat Commun 9.
24. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, et al. (2012) Genome-wide associa-
tion study identifies multiple loci influencing human serum metabolite levels. Nat Genet 44: 269–276.
https://doi.org/10.1038/ng.1073 PMID: 22286219
25. Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, et al. (2016) Genome-wide study for circulating
metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun 7: 11122. https://
doi.org/10.1038/ncomms11122 PMID: 27005778
26. Davis JP, Huyghe JR, Locke AE, Jackson AU, Sim X, et al. (2017) Common, low-frequency, and rare
genetic variants associated with lipoprotein subclasses and triglyceride measures in Finnish men from
the METSIM study. PLoS Genet 13: e1007079. https://doi.org/10.1371/journal.pgen.1007079 PMID:
29084231
27. Dewey FE, Gusarova V, O’Dushlaine C, Gottesman O, Trejos J, et al. (2016) Inactivating Variants in
ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med 374: 1123–1133. https://doi.org/10.
1056/NEJMoa1510926 PMID: 26933753
28. Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, et al. (2016) Distribution and clinical
impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science
354.
29. Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, et al. (2016) M-CAP eliminates a
majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet 48: 1581–
1586. https://doi.org/10.1038/ng.3703 PMID: 27776117
30. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, et al. (2016) The genetic architec-
ture of type 2 diabetes. Nature 536: 41–47. https://doi.org/10.1038/nature18642 PMID: 27398621
31. Kiezun A, Garimella K, Do R, Stitziel NO, Neale BM, et al. (2012) Exome sequencing and the genetic
basis of complex traits. Nat Genet 44: 623–630. https://doi.org/10.1038/ng.2303 PMID: 22641211
32. Turcot V, Lu Y, Highland HM, Schurmann C, Justice AE, et al. (2018) Protein-altering variants associ-
ated with body mass index implicate pathways that control energy intake and expenditure in obesity.
Nat Genet 50: 26–41. https://doi.org/10.1038/s41588-017-0011-x PMID: 29273807
33. Drenos F, Davey Smith G, Ala-Korpela M, Kettunen J, Wurtz P, et al. (2016) Metabolic Characterization
of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects. Circ Cardio-
vasc Genet 9: 231–239. https://doi.org/10.1161/CIRCGENETICS.115.001302 PMID: 27114411
34. Rhee EP, Yang Q, Yu B, Liu X, Cheng S, et al. (2016) An exome array study of the plasma metabolome.
Nat Commun 7: 12360. https://doi.org/10.1038/ncomms12360 PMID: 27453504
35. Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P (2015) Adjusting for heritable covariates can
bias effect estimates in genome-wide association studies. Am J Hum Genet 96: 329–339. https://doi.
org/10.1016/j.ajhg.2014.12.021 PMID: 25640676
36. Aschard H, Guillemot V, Vilhjalmsson B, Patel CJ, Skurnik D, et al. (2017) Covariate selection for asso-
ciation screening in multiphenotype genetic studies. Nat Genet 49: 1789–1795. https://doi.org/10.1038/
ng.3975 PMID: 29038595
37. Lee S, Wu MC, Lin X (2012) Optimal tests for rare variant effects in sequencing association studies. Bio-
statistics 13: 762–775. https://doi.org/10.1093/biostatistics/kxs014 PMID: 22699862
38. Zaykin DV (2011) Optimally weighted Z-test is a powerful method for combining probabilities in meta-
analysis. J Evol Biol 24: 1836–1841. https://doi.org/10.1111/j.1420-9101.2011.02297.x PMID:
21605215
PLOS GENETICS The influence of rare variants in circulating metabolic biomarkers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008605 March 9, 2020 17 / 19
39. Grevengoed TJ, Martin SA, Katunga L, Cooper DE, Anderson EJ, et al. (2015) Acyl-CoA synthetase 1
deficiency alters cardiolipin species and impairs mitochondrial function. J Lipid Res 56: 1572–1582.
https://doi.org/10.1194/jlr.M059717 PMID: 26136511
40. Yan S, Yang XF, Liu HL, Fu N, Ouyang Y, et al. (2015) Long-chain acyl-CoA synthetase in fatty acid
metabolism involved in liver and other diseases: an update. World J Gastroenterol 21: 3492–3498.
https://doi.org/10.3748/wjg.v21.i12.3492 PMID: 25834313
41. Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark UK, et al. (2013) MYC inhibition induces
metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A
110: 10258–10263. https://doi.org/10.1073/pnas.1222404110 PMID: 23733953
42. Li LO, Ellis JM, Paich HA, Wang S, Gong N, et al. (2009) Liver-specific loss of long chain acyl-CoA syn-
thetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid com-
position. J Biol Chem 284: 27816–27826. https://doi.org/10.1074/jbc.M109.022467 PMID: 19648649
43. Scott RA, Scott LJ, Magi R, Marullo L, Gaulton KJ, et al. (2017) An Expanded Genome-Wide Associa-
tion Study of Type 2 Diabetes in Europeans. Diabetes 66: 2888–2902. https://doi.org/10.2337/db16-
1253 PMID: 28566273
44. Yang L, Yang Y, Si D, Shi K, Liu D, et al. (2017) High expression of long chain acyl-coenzyme A synthe-
tase 1 in peripheral blood may be a molecular marker for assessing the risk of acute myocardial infarc-
tion. Exp Ther Med 14: 4065–4072. https://doi.org/10.3892/etm.2017.5091 PMID: 29104625
45. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in
untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124.
https://doi.org/10.1126/science.6719137 PMID: 6719137
46. Emanuel BS, Balaban G, Boyd JP, Grossman A, Negishi M, et al. (1985) N-myc amplification in multiple
homogeneously staining regions in two human neuroblastomas. Proc Natl Acad Sci U S A 82: 3736–
3740. https://doi.org/10.1073/pnas.82.11.3736 PMID: 2582423
47. Sato T, Gotoh M, Kiyohara K, Kameyama A, Kubota T, et al. (2003) Molecular cloning and characteriza-
tion of a novel human beta 1,4-N-acetylgalactosaminyltransferase, beta 4GalNAc-T3, responsible for
the synthesis of N,N’-diacetyllactosediamine, galNAc beta 1-4GlcNAc. J Biol Chem 278: 47534–
47544. https://doi.org/10.1074/jbc.M308857200 PMID: 12966086
48. Morgan H, Beck T, Blake A, Gates H, Adams N, et al. (2010) EuroPhenome: a repository for high-
throughput mouse phenotyping data. Nucleic Acids Res 38: D577–585. https://doi.org/10.1093/nar/
gkp1007 PMID: 19933761
49. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, et al. (2015) New genetic loci link
adipose and insulin biology to body fat distribution. Nature 518: 187–196. https://doi.org/10.1038/
nature14132 PMID: 25673412
50. Wood AR, Esko T, Yang J, Vedantam S, Pers TH, et al. (2014) Defining the role of common variation in
the genomic and biological architecture of adult human height. Nat Genet 46: 1173–1186. https://doi.
org/10.1038/ng.3097 PMID: 25282103
51. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, et al. (2004) Systematic analysis and nomencla-
ture of mammalian F-box proteins. Genes Dev 18: 2573–2580. https://doi.org/10.1101/gad.1255304
PMID: 15520277
52. Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER (2014) The pivotal role of pyruvate dehydroge-
nase kinases in metabolic flexibility. Nutr Metab (Lond) 11: 10.
53. Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, et al. (2018) Lipids, Lipoproteins, and
Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol 71: 620–632. https://doi.
org/10.1016/j.jacc.2017.12.006 PMID: 29420958
54. Dron JS, Wang J, Low-Kam C, Khetarpal SA, Robinson JF, et al. (2017) Polygenic determinants in
extremes of high-density lipoprotein cholesterol. J Lipid Res 58: 2162–2170. https://doi.org/10.1194/jlr.
M079822 PMID: 28870971
55. Teslovich TM, Kim DS, Yin X, Stancakova A, Jackson AU, et al. (2018) Identification of seven novel loci
associated with amino acid levels using single-variant and gene-based tests in 8545 Finnish men from
the METSIM study. Hum Mol Genet 27: 1664–1674. https://doi.org/10.1093/hmg/ddy067 PMID:
29481666
56. Moore C, Sambrook J, Walker M, Tolkien Z, Kaptoge S, et al. (2014) The INTERVAL trial to determine
whether intervals between blood donations can be safely and acceptably decreased to optimise blood
supply: study protocol for a randomised controlled trial. Trials 15: 363. https://doi.org/10.1186/1745-
6215-15-363 PMID: 25230735
57. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, et al. (2016) The Allelic Landscape of Human Blood Cell
Trait Variation and Links to Common Complex Disease. Cell 167: 1415–1429 e1419. https://doi.org/10.
1016/j.cell.2016.10.042 PMID: 27863252
PLOS GENETICS The influence of rare variants in circulating metabolic biomarkers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008605 March 9, 2020 18 / 19
58. Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, et al. (2016) Rare loss-of-function variants in
SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 19: 571–577.
https://doi.org/10.1038/nn.4267 PMID: 26974950
59. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinfor-
matics 25: 1754–1760. https://doi.org/10.1093/bioinformatics/btp324 PMID: 19451168
60. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit:
a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:
1297–1303. https://doi.org/10.1101/gr.107524.110 PMID: 20644199
61. Jun G, Flickinger M, Hetrick KN, Romm JM, Doheny KF, et al. (2012) Detecting and estimating contami-
nation of human DNA samples in sequencing and array-based genotype data. Am J Hum Genet 91:
839–848. https://doi.org/10.1016/j.ajhg.2012.09.004 PMID: 23103226
62. Consortium UK, Walter K, Min JL, Huang J, Crooks L, et al. (2015) The UK10K project identifies rare
variants in health and disease. Nature 526: 82–90. https://doi.org/10.1038/nature14962 PMID:
26367797
63. Soininen P, Kangas AJ, Wurtz P, Tukiainen T, Tynkkynen T, et al. (2009) High-throughput serum NMR
metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134: 1781–1785.
https://doi.org/10.1039/b910205a PMID: 19684899
64. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, et al. (2016) The Ensembl Variant Effect Predictor.
Genome Biol 17: 122. https://doi.org/10.1186/s13059-016-0974-4 PMID: 27268795
65. R Core Team (2015) R: A language and environment for statistical computing. R Foundation for Statis-
tical Computing, Vienna, Austria.
66. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res 38: e164. https://doi.org/10.1093/nar/gkq603 PMID:
20601685
67. Lee S, Teslovich TM, Boehnke M, Lin X (2013) General framework for meta-analysis of rare variants in
sequencing association studies. Am J Hum Genet 93: 42–53. https://doi.org/10.1016/j.ajhg.2013.05.
010 PMID: 23768515
68. Pinero J, Bravo A, Queralt-Rosinach N, Gutierrez-Sacristan A, Deu-Pons J, et al. (2017) DisGeNET: a
comprehensive platform integrating information on human disease-associated genes and variants.
Nucleic Acids Res 45: D833–D839. https://doi.org/10.1093/nar/gkw943 PMID: 27924018
69. Pinero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, et al. (2015) DisGeNET: a dis-
covery platform for the dynamical exploration of human diseases and their genes. Database (Oxford)
2015: bav028.
70. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on
genomes, pathways, diseases and drugs. Nucleic Acids Res 45: D353–D361. https://doi.org/10.1093/
nar/gkw1092 PMID: 27899662
71. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:
27–30. https://doi.org/10.1093/nar/28.1.27 PMID: 10592173
72. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M (2016) KEGG as a reference resource for
gene and protein annotation. Nucleic Acids Res 44: D457–462. https://doi.org/10.1093/nar/gkv1070
PMID: 26476454
73. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, et al. (2018) The Reactome Pathway
Knowledgebase. Nucleic Acids Res 46: D649–D655. https://doi.org/10.1093/nar/gkx1132 PMID:
29145629
74. Milacic M, Haw R, Rothfels K, Wu G, Croft D, et al. (2012) Annotating cancer variants and anti-cancer
therapeutics in reactome. Cancers (Basel) 4: 1180–1211.
75. MacArthur J, Bowler E, Cerezo M, Gil L, Hall P, et al. (2017) The new NHGRI-EBI Catalog of published
genome-wide association studies (GWAS Catalog). Nucleic Acids Res 45: D896–D901. https://doi.org/
10.1093/nar/gkw1133 PMID: 27899670
76. Dewey M (2020) metap: meta-analysis of significance values. R package version 1.3.
77. Gopinathrao G (2007) Image for “Regulation of pyruvate dehydrogenase (PDH) complex”. Reactome,
release 65, https://doi.org/10.3180/REACT_12528.1
PLOS GENETICS The influence of rare variants in circulating metabolic biomarkers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008605 March 9, 2020 19 / 19
